Virtual Screening and Experimental Testing of B1 Metallo-β-lactamase Inhibitors.
Ontology highlight
ABSTRACT: The global rise of metallo-β-lactamases (MBLs) is problematic due to their ability to inactivate most β-lactam antibiotics. MBL inhibitors that could be coadministered with and restore the efficacy of β-lactams are highly sought after. In this study, we employ virtual screening of candidate MBL inhibitors without thiols or carboxylates to avoid off-target effects using the Avalanche software package, followed by experimental validation of the selected compounds. As target enzymes, we chose the clinically relevant B1 MBLs NDM-1, IMP-1, and VIM-2. Among 32 compounds selected from an approximately 1.5 million compound library, 6 exhibited IC50 values less than 40 μM against NDM-1 and/or IMP-1. The most potent inhibitors of NDM-1, IMP-1, and VIM-2 had IC50 values of 19 ±
SUBMITTER: Kang JS
PROVIDER: S-EPMC6527342 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA